학술논문
Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B
Document Type
article
Source
Haemophilia. 27(4)
Subject
Language
Abstract
AimPhase 2b study to assess efficacy, safety, thrombogenicity, immunogenicity and tolerability with 28 days of daily dosing of subcutaneous (SQ) dalcinonacog alfa as prophylaxis for haemophilia B (HB).MethodsAdult males with a confirmed diagnosis of congenital HB (factor IX [FIX] activity